A Beacon of Hope: National TMS Therapy Day Launched to Combat Treatment-Resistant Depression!

Neuronetics ignites hope with the first National TMS Therapy Awareness Day on May 14th, a new initiative during Mental Health Awareness Month¹.
Transcranial Magnetic Stimulation (TMS) is spotlighted as a proven, non-drug lifeline for individuals battling Major Depressive Disorder (MDD), depression with anxiety, and OCD, particularly when antidepressants have failed^{1, 3}.
NeuroStar TMS, a pioneering force, recently gained FDA clearance for adolescents, dramatically expanding access to its life-altering, precision-targeted therapy⁷.

In the silent struggle where conventional treatments often fall short, millions grapple with the suffocating weight of depression. But now, a powerful new voice cuts through the despair. Neuronetics, Inc. (NASDAQ: STIM) today unleashes a surge of optimism, launching the inaugural National TMS Therapy Awareness Day, to be championed annually on May 14th. This landmark day, strategically set within May’s Mental Health Awareness Month, serves as a resounding call to action for all those who feel adrift in their mental health journey.

"National TMS Awareness Day is about giving hope to people who haven’t found relief," declares Keith Sullivan, President and CEO of Neuronetics, emphasizing the mission to be a "driving force" in the national mental health conversation. For far too many, the cycle of trying multiple antidepressants without adequate relief leads to a feeling of being "stuck or discouraged." This initiative aims to shatter the shadows surrounding Transcranial Magnetic Stimulation (TMS) – a revolutionary, non-drug therapy like NeuroStar. First FDA-cleared in 2008 for adult treatment-resistant depression, NeuroStar has now, in a significant 2024 advancement, received FDA clearance for adolescents aged 15-21⁷, opening new doors for younger patients. TMS is a widely adopted, evidence-backed modality, with studies showing remission rates of 30% to 40% in MDD cases⁶ and often fewer side effects compared to traditional medications.

The power of NeuroStar lies in its precision. "Our unique coil design is built to deliver focused magnetic pulses exactly where they’re needed," explains Geoffrey Grammer, MD, Chief Medical Officer of Neuronetics. This, combined with advanced Contact Sensing, ensures each session is consistently effective. With over 300 million people having insurance plans that cover NeuroStar TMS, including Medicare and Tricare, this transformative treatment is becoming increasingly accessible. Inspiring stories, like that of patient advocate Kristen Gingrich who found her path to recovery with NeuroStar after years of struggle, are now being shared across social media, lighting the way for others to explore non-drug options^{1, 2}.

As Neuronetics continues its legacy by presenting new data at the 2025 American Psychiatric Association Annual Meeting, the message is unequivocal: mental health is paramount. National TMS Therapy Awareness Day celebrates the profound, real-world impact of NeuroStar, empowering patients, caregivers, and healthcare providers with the knowledge that effective, non-drug treatments are available and within reach. To learn more about this vital initiative and NeuroStar TMS therapy, visit TMSAwareness.com⁴.

A Beacon of Hope: National TMS Therapy Day Launched to Combat Treatment-Resistant Depression!

References

Stay Updated!